The interest in Blockchain and distributed ledger technology (DLT) has exploded in recent years with a large focus on the financial industry. Meanwhile, medical and pharmaceutical companies around the world are looking to DLT as a means of solving, securing, and streamlining their businesses. While there are many applications for DLT within the medical industry, one area where the technology excels is within supply chains.
NHS England has laid out plans for England to become the first country to eliminate hepatitis C, at least five years earlier than the World Health Organisation(WHO)’s target date of 2030.
The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
Surgeons use Microsoft HoloLens headsets while operating on patients undergoing reconstructive lower limb surgery.
This year could see a transformation in the Japanese pharma market, according to a new report, with strong growth stemming from increased use of generics, biosimilars and stronger links with the global industry.
In many ways, 2017 was a banner year for digital health funding, according to Rock Health's annual report, which puts funding for the year at a record $5.8 billion.
Washington University School of Medicine sleep specialist Yo-El Ju, MD, led a research team that found circadian rhythm disruptions occur in people whose memories are intact but whose brain scans show early, preclinical evidence of Alzheimer's disease. She previously had discovered that people with clinical symptoms of Alzheimer's have disturbances in their internal body clocks that affect the sleep/wake cycle. Credit: Washington University School of Medicine.
Enzychem Lifesciences, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to EC-18 for the treatment of Acute Radiation Syndrome (ARS).
NICE has become the latest organisation to champion digital health, recommending that the NHS should trial an online and mobile programme to treat depression.
The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.